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Etoposide is commonly used in a variety of malignancies. A well known but rare toxicity are hypersensitivity reactions, usually
manifested by chest discomfort, dyspnoea, bronchospasm and hypotension. We report the details of a patient who developed
hypersensitivity reactions to intravenous etoposide, but subsequently tolerated the administration of intravenous etoposide
phosphate with no sequalae.
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The podophyllotoxin etoposide has been used clinically for over 30
years. It is active in the treatment of a variety of malignant condi-
tions and can be administered in either an i.v. or in an oral form.
Intravenous etoposide is generally well tolerated. A well known but
rare toxicity is a type I hypersensitivity reaction, manifested by
dyspnoea, chest discomfort, hypotension, bronchospasm and/or
skin ﬂushing (Weiss, 1996; O’Brien and Souberbielle, 1992). It
remains unclear whether this reaction is due to either the active
drug or the solvent (Weiss, 1996).
We report here the details of a patient who, despite experiencing
a hypersensitivity reaction to intravenous etoposide, tolerated the
subsequent administration of intravenous etoposide phosphate
without any allergic sequalae. A test dose of etoposide phosphate
was not administered, and premedication, which was administered
initially, was discontinued. This case highlights three important
aspects in patients experiencing hypersensitivity reaction to etopo-
side: (i) etoposide phosphate can be considered as an appropriate
alternative; (ii) premedication may not be required; and (iii) the
hypersensitivity reaction is more likely due to the solvent.
CASE DESCRIPTION
A 19-year-old male with a newly diagnosed primary mediastinal
non-seminomatous germ cell tumour was admitted for treatment
with the standard BEP regimen. This consisted of weekly i.v. bleo-
mycin 30000 iu and 3-weekly cycles of i.v. etoposide 100 mg m
72
day
71 for 5 days and cisplatin 20 mg m
72 day
71 for 5 days
(Williams et al, 1987). The patient had no known allergies. Follow-
ing premedication with i.v. tropisetron (5 mg) and dexamethasone
(8 mg) administration of etoposide was commenced (200 mg in
500 ml of sodium chloride 0.9%, over 60 min). Within minutes
of commencement of the ﬁrst dose of etoposide the patient
complained of generalized discomfort and shortness of breath.
He was found to be hypotensive (BP=95/60), tachycardic
(PR=110) and had an oxygen saturation of 80% on room air.
The infusion was immediately ceased. Treatment was begun with
i.v. hydration, with bolus doses of hydrocortisone (100 mg) and
promethazine (50 mg). Oxygen (6 l min
71) and nebulized salbuta-
mol were also given. The patient improved rapidly with complete
resolution of his symptoms, and was comfortable within 1 h. No
bleomycin or cisplatin was administered.
Germ cell tumours of the mediastinum are potentially curable,
and etoposide is considered to be a critical component of an
effective treatment schedule. Thus, it was felt that in this case
continued use of etoposide was warranted. In light of this deci-
sion, cycle 1 of chemotherapy was recommenced a few days
later but with etoposide replaced by the equivalent dose of etopo-
side phosphate. The patient was premedicated with hydrocortisone
(100 mg) and promethazine (25 mg). No reaction occurred with
the administration of the etoposide phosphate and the cisplatin
and bleomycin were also administered without problem. The same
procedure was followed the next day (day 2) with the same speci-
ﬁc pre-medication followed by etoposide phosphate and then
cisplatin. Again, there was no evidence of a HSR. As the patient
experienced drowsiness with promethazine, and in view of the fact
that there had been no further evidence of a HSR, the last three
doses of etoposide phosphate in cycle 1 were given without speci-
ﬁc anti-HSR premedication, although oral dexamethasone at a
dose of 4 mg twice daily was given as anti-emetic prophylaxis.
There was no evidence of a HSR on any of these days. Subsequent
cycles of BEP have been administered using standard anti-emetic
pre-medication but with no histamine antagonists, and there have
been no complications.
DISCUSSION
Hypersensitivity reactions occur as an adverse effect of cancer
chemotherapy in up to 40% of patients (Weiss, 1996; O’Brien
and Souberbielle, 1992). Etoposide has been reported to cause a
hypersensitivity reaction in 1–3% of patients (Weiss, 1996), but
one study observed hypersensitivity reactions in 33% of children
treated for acute leukaemia (Kellie et al, 1991). In most patients
the reactions occur within the ﬁrst 5 to 10 min of infusion and
complete recovery is usual once the infusion is discontinued.
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several hours after administration (Weiss, 1996). There are no
known risk factors for developing a HSR to etoposide, and in
few of the reported cases do the patients have a history of drug
allergy (Kasperek and Black, 1992; Bernstein and Troner, 1999;
Athanassiou et al, 1988; De Souza et al, 1994; Tester et al, 1990;
Hoetelman et al, 1996; Siderov and Zalcberg, 1994; Tucci and
Pirtoli, 1985; Donegan, 1989; Eschalier et al, 1988; Schacter, 1996).
The mechanism underling hypersensitivity reactions to epipodo-
phyllotoxins have not been fully elucidated. Typically, type I HSR
occur, although type II reactions have also been reported (Weiss,
1996; O’Brien and Souberbielle, 1992; Kasperek and Black, 1992).
Bernstein and Troner (1999) have attributed etoposide HSRs to
the concentration of the drug and the rate of infusion. However,
other authors have reported HRSs in patients receiving a wide
range of etoposide concentrations, weakening this hypothesis
(Kasperek and Black, 1992; Bernstein and Troner, 1999; Athanas-
siou et al, 1988; De Souza et al, 1994; Tester et al, 1990;
Hoetelman et al, 1996; Siderov and Zalcberg, 1994; Tucci and
Pirtoli, 1985; Donegan, 1989; Eschalier et al, 1988; Schacter,
1996). Another suggested hypothesis is that the vehicle used to
dissolve the etoposide (benzyl alcohol and polysorbate (tween)
80) is responsible for the HSR (Weiss, 1996). In animal models,
polysorbate has been shown to induce histamine release and cause
hypersensitivity reactions (Eschalier et al, 1988). The fact that there
have been no reports of hypersensitivity reactions caused by oral
etoposide, a formulation containing citric acid, glycerin and poly-
ethylene glycol, but no polysorbate 80, provides additional support
for this hypothesis (Weiss, 1996). Etoposide phosphate, a water
soluble prodrug of etoposide, was designed to obviate problems
associated with etoposide (Schacter, 1996). Formulations of etopo-
side phosphate do not contain polysorbate 80 and there have been
no case reports in the literature of HSR to etoposide phosphate.
Therefore the substitution of etoposide phosphate in patients
who experience a HSR to etoposide rather than rechallenge would
seem appropriate. Another possible alternative is the use of oral
etoposide (Siderov and Zalcberg, 1994).
Our patient was retreated using etoposide phosphate at an
equivalent dose. The patient was premedicated with hydrocortisone
(100 mg) and promethazine (25 mg) and no test dose of etoposide
phosphate was administered. After 2 days of therapy with etoposide
phosphate, the speciﬁc HSR premedication was discontinued.
However, the patient continued to have oral dexamethasone
(4 mg twice daily) as anti-emetic prophylaxis. No HSR occurred
at any stage of cycle 1, and subsequent cycles of BEP have been
administered with no complications.
This case highlights that patients experiencing HSR to etoposide
can be successfully treated with etoposide phosphate without
adverse sequalae. Premedication appears prudent as initial therapy,
but can be successfully weaned. This case supports the hypothesis
that polysorbate 80 is a likely causative factor in HSRs to etopo-
side. The only other published report of a successful substitution
with etoposide phosphate in a patient who experienced a HSR to
etoposide did not conclude whether the premedication schedule
used (which included both H1 and H2 antihistamine agents) or
the use of etoposide phosphate was the factor preventing the
HSR from reoccurring (Bernstein and Troner, 1999).
Hypersensitivity reactions to etoposide are uncommon, but can
be life threatening. The subsequent management of patients experi-
encing a HSR to etoposide is usually the omission of etoposide
from the chemotherapy regimen (Athanassiou et al, 1988; De Souza
et al, 1994; Tucci and Pirtoli, 1985; Donegan, 1989). However,
since etoposide is considered a critical component of therapy, its
omission in a young patient with a potentially curable malignancy
was thought inappropriate. Therefore, in similar situations where
subsequent doses of etoposide are deemed necessary, replacement
with etoposide phosphate is a reasonable and viable alternative.
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